anti-CD80 antibody + anti-CD86 antibody

This combination therapy consists of humanized monoclonal antibodies targeting B7.1 (CD80) and B7.2 (CD86). Developed by the Dana-Farber Cancer Institute, it is used for the *ex vivo* treatment of donor bone marrow prior to haploidentical transplantation. By blocking the interaction between B7 ligands on antigen-presenting cells and the CD28 receptor on T cells, the treatment prevents the costimulatory signals necessary for T-cell activation. This process, known as alloanergization, aims to induce alloantigen-specific hyporesponsiveness in donor cells, thereby reducing the risk of graft-versus-host disease (GVHD) while preserving the graft-versus-leukemia effect. It has been investigated in Phase 1 trials for patients with high-risk hematologic malignancies and bone marrow failure.

Other names

anti-B7.1 antibody + anti-B7.2 antibodyanti-B7.1 and anti-B7.2 antibodiesanti-B-7.1 and anti-B7.2 antibodiesanti-B 7.1 and anti-B7.2 antibodiesB7.1/B7.2 costimulatory blockade